---
title: "BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227910578.md"
description: "BridgeBio Pharma announced that the European Commission has approved Beyonttra (acoramidis) for treating transthyretin amyloidosis in adults with cardiomyopathy. Bayer will launch the drug in the EU in H1 2025. BridgeBio expects a $75 million milestone payment and tiered royalties from Bayer's sales in the EU. Acoramidis is already FDA-approved as Attruby in the US."
datetime: "2025-02-11T14:46:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227910578.md)
  - [en](https://longbridge.com/en/news/227910578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227910578.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/227910578.md) | [繁體中文](https://longbridge.com/zh-HK/news/227910578.md)


# BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis

BridgeBio Pharma said Tuesday that the European Commission has granted marketing authorization for acoramidis, under the brand name Beyonttra, to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy.

BridgeBio said German pharmaceutical company Bayer will launch acoramidis in H1 of 2025 in the European Union.

BridgeBio also said that based on its licensing agreement with Bayer, it expects to receive a $75 million milestone payment as well as royalties in a tiered structure on sales of acoramidis in the EU.

Acoramidis has already been approved by the US Food and Drug Administration under the brand Attruby.

### Related Stocks

- [BridgeBio Pharma, Inc. (BBIO.US)](https://longbridge.com/en/quote/BBIO.US.md)

## Related News & Research

- [BUZZ-BridgeBio rises after $550 mln convertible debt offering](https://longbridge.com/en/news/272850047.md)
- [BridgeBio Pharma CEO Neil Kumar Reports Sale of Common Shares](https://longbridge.com/en/news/272345479.md)
- [BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears](https://longbridge.com/en/news/272096382.md)
- [BridgeBio Pharma Highlights Pipeline Progress and Patient Impact in New Corporate Presentation](https://longbridge.com/en/news/272295165.md)
- [BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference](https://longbridge.com/en/news/272361328.md)